Investor Overview
News
- Kindred Biosciences Initiates Pivotal Efficacy Study of Tirnovetmab (Interleukin-31) Monoclonal Antibody for Canine Atopic DermatitisDecember 22, 2020 8:31 AM EST
- Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study for Anti-TNFα Antibody for Canine Inflammatory Bowel DiseaseDecember 21, 2020 8:31 AM EST
- Kindred Biosciences Announces Agreement Granting Elanco Exclusive Global Rights for its Parvovirus Monoclonal AntibodyDecember 11, 2020 8:00 AM EST
Events
- Monday, December 7, 2020 10:00 AM EST
- Thursday, November 19, 2020
- Tuesday, November 17, 2020 from 2:40 PM to 3:10 PM EST
|
||||||||||||||||
KindredBio proudly supports
Rabies Free Africa
Investor Overview
KindredBio is focused on bringing innovative biologics and technologies to veterinary medicine to address unmet clinical needs and provide benefits to pets.
Stock Information
News
Kindred Biosciences Initiates Pivotal Efficacy Study of Tirnovetmab (Interleukin-31) Monoclonal Antibody for Canine Atopic Dermatitis
December 22, 2020
SAN FRANCISCO , Dec. 22, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:...
Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study for Anti-TNFα Antibody for Canine Inflammatory Bowel Disease
December 21, 2020
SAN FRANCISCO , Dec. 21, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:...
Kindred Biosciences Announces Agreement Granting Elanco Exclusive Global Rights for its Parvovirus Monoclonal Antibody
December 11, 2020
SAN FRANCISCO , Dec. 11, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:...